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ABSTRACT
Objectives: To determine the utility of the cell transfer 
technique (CTT) for BRAF molecular testing on thyroid fine-
needle aspiration (FNA) specimens.
Methods: Polymerase chain reaction (PCR)–based BRAF 
molecular testing was performed on tissues obtained 
through CTT from both air-dried and ethanol-fixed direct 
smears of thyroid FNA specimens and then compared with 
the corresponding thyroidectomy formalin-fixed, paraffin-
embedded (FFPE) tissues on 30 cases.
Results: BRAF testing was successfully performed on 29 
of 30 air-dried CTT, 27 of 30 ethanol-fixed CTT, and 27 
of 30 FFPE tissues. The results exhibited 11, 13, and 13 
BRAF mutations and 18, 14, and 14 wild types for the 
air-dried CTT, the ethanol-fixed CTT, and the FFPE tissues, 
respectively. The concordance rate was 96% between 
air-dried and ethanol-fixed CTT tissues, 88% between 
air-dried CTT and FFPE tissues, and 92% between ethanol-
fixed CTT and FFPE tissues.
Conclusions: PCR-based BRAF mutational testing can be 
reliably performed on the direct smears of the thyroid FNA 
specimens through the application of CTT.
Papillary thyroid carcinoma (PTC) accounts for 80% of 
all thyroid cancers in the United States, making it the most 
common thyroid malignancy.1 Fine-needle aspiration (FNA) 
biopsy has emerged as an important diagnostic tool in the 
workup of suspicious thyroid nodules. Papillary carcinoma, 
in particular, displays characteristic nuclear features that 
often allow for a cytologic diagnosis based on morphology 
alone. Some cases, however, have only a few of the diagnos-
tic features or are of limited cellularity. These cases are often 
placed into the category of follicular lesions of undetermined 
significance (FLUS) or suspicious for malignancy.
In recent years, it has been shown that a mutation of 
the BRAF gene is the most common genetic alteration in 
PTC and is detected in 29% to 69% of PTCs.2-4 Most impor-
tant, when dealing with primary thyroid neoplasms, BRAF 
mutations are found in PTC and in poorly differentiated or 
anaplastic thyroid carcinoma derived from PTC.5 Therefore, 
molecular techniques that can identify this BRAF mutation 
can be an important ancillary diagnostic tool in the diagnosis 
of PTC, especially in cases that would otherwise be classi-
fied as atypia of undetermined significance or suspicious for 
malignancy. In addition, numerous studies have shown that 
BRAF mutations in PTC are associated with characteristics 
that are predictive of tumor progression and recurrence 
such as extracapsular invasion, lymph node metastasis, and 
advanced tumor stage.6 Finally, with the advent of novel 
pharmaceutical agents that target the mitogen-activated pro-
tein kinase pathway that is abnormally activated by BRAF 
mutations, detection of BRAF mutations will likely have an 
impact on the treatment of PTC. Thus, analysis of specimens 
for the BRAF mutation can have diagnostic, prognostic, and 
therapeutic implications.
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The use of formalin-fixed, paraffin-embedded (FFPE) cell 
blocks prepared from FNA specimens is generally considered 
a reliable source of tumor cells for molecular assessment as 
well as immunohistochemical studies that can detect BRAF 
mutations.7 In particular, thyroid FNA is commonly used 
for preoperational diagnosis because high vascularity of the 
thyroid tissue can cause complications with more invasive 
procedures such as core biopsy. Cell blocks, however, are not 
routinely made or sometimes lack adequate cellularity to per-
form these ancillary studies. At our institution, the cell transfer 
technique (CTT), using direct cytologic smears as a source of 
tumor cells, has proven to be a reliable method for performing 
immunohistochemical and molecular studies when cell blocks 
lack adequate cellularity.8 Our goal, therefore, was to establish 
CTT as a viable option for isolating tumor cells for ancillary 
BRAF mutation analysis via the polymerase chain reaction 
(PCR)–based platforms. To validate this technique, we con-
currently tested corresponding FFPE tissue from follow-up 
surgical resection alongside tissue obtained from direct smears.
Materials and Methods
This study was approved by the Indiana University 
Institutional Review Board. A computerized search of our 
anatomic pathology information system was performed for a 
26-month period (January 2011 through February 2013). To 
have an adequate number of positive BRAF mutation cases, 
we selected thyroidectomy specimens with final diagnoses 
of PTC and two cases of follicular neoplasm that had cor-
responding FNA performed. Cases of benign thyroid lesions 
were also included.
In total, there were 30 FNA specimens from 30 patients, 
including six men and 24 women in our study. The patients’ 
ages ranged from 26 to 84 years, with a median age of 45 
years and a mean age of 45.7 years. Nodules were present in 
the left lobe in 15 cases, in the right lobe in 14 cases, and in 
the isthmus in one case. The final histologic diagnoses of 30 
cases included 18 classic PTCs, four follicular variant PTCs, 
one follicular carcinoma, one follicular adenoma, and six 
benign nonneoplastic lesions.
The slides from direct smears of thyroid aspirates and 
histologic slides of the corresponding thyroid nodules were 
reexamined. Both cytologic and surgical pathology reports 
as well as pertinent clinical history and radiographic results 
were reviewed. One ethanol-fixed smear, one air-dried direct 
smear, and one corresponding FFPE block that contained 
lesional cells were selected for BRAF molecular testing. The 
areas on the direct smears containing abnormal cells were 
marked by a pathologist (H.H.W.), and photographs were 
taken from these areas, in which the tumor cells of interest 
were then collected by CTT and sent for molecular testing.
Cell Transfer Technique
CTT was performed using clean technique as follows: 
(1) the coverslip was removed using fresh histologic-grade 
xylene (Fisher Scientific, Pittsburgh, PA), (2) a thin layer 
of Mount Quick media (Daido Sangyo, Tokyo, Japan) was 
spread uniformly over the top of the cellular material, (3) the 
slide was then placed in a 60°C oven for approximately 2 to 
3 hours (or until hardened to the touch), (4) a Sharpie marker 
was used on the surface of the dried media to divide the slide 
into multiple areas of interest, (5) the slide was then placed 
into a clean Coplin jar of deionized water and submerged 
into a warm water bath at 45 ± 3°C for 30 minutes to 2 hours 
or until the media were soft enough to easily peel away from 
the slide, and (6) the media were cut along the marked areas, 
and each cut section was placed in an Eppendorf 2.0-mL 
safe-lock centrifuge tube and sent for molecular testing.
DNA Extraction
DNA extraction from FFPE tissue and cytologic speci-
mens was performed using the Qiagen QIAamp DNA FFPE 
Tissue Kit (Qiagen, Valencia, CA). A microdissection was 
performed for the extraction of DNA from FFPE tissue. For 
the cytologic specimens, a modification from the manufac-
turer’s recommendations was made. Samples were incubat-
ed at room temperature for 5 minutes with 1 mL xylene and 
then centrifuged at 15,000 rpm for 5 minutes. Xylene was 
removed from the pellet and followed by the ethanol wash 
recommended by the manufacturer. DNA concentration was 
determined using the NanoDrop spectrophotometer (Thermo 
Scientific, Wilmington, DE).
BRAF Mutations
Samples were analyzed by a Qiagen BRAF RGQ 
PCR run on the Rotor-Gene Q MDx (Qiagen) following 
the manufacturer’s recommendations. Genomic DNA was 
used to detect five mutations in codon 600 of the BRAF 
gene. The real-time PCR detection system employed both 
Scorpions and Amplification Refractory Mutation System 
technologies (Qiagen) on the Rotor-Gene Q instrument. 
This assay can detect somatic mutations, including V600E, 
V600E complex, V600D, V600K, and V600R, although it 
is unable to differentiate the V600E and V600E complex 
mutations. Overall, this is a two-step procedure, with the 
first step being a control assay to assess the total BRAF DNA 
content in a sample and the second step combining both the 
mutation and control assays to determine the presence or 
absence of mutated DNA. The threshold at which the signal 
is detected above background is called the cycle threshold. 
Sample delta cycle threshold values are calculated as the 
difference between the mutation assay cycle threshold and 
the wild-type assay cycle threshold from the same sample. 
Samples are subsequently classified as “mutation positive” 
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if they give a delta cycle threshold less than the stated cutoff 
value for the assay. If the delta cycle threshold is above the 
cutoff, the sample is classified as “mutation not detected.” 
Appropriate positive and negative controls were run with 
each sample.
Results
All CTT tissue submitted for BRAF testing contained 
more than 100 cells. The DNA yield ranged from 0.1 to 31.5 
mg (median, 3.7 mg; mean, 9.6 mg) for ethanol-fixed and 
0.2 to 16.9 mg (median, 5.5 mg; mean, 4.7 mg) for air-dried 
cytologic samples and 28.1 to 425.1 mg (median, 123.6 mg; 
mean, 158.2 mg) for FFPE tissues.
BRAF testing was successfully performed on 29 of 30 
air-dried CTT (97%), 27 of 30 ethanol-fixed CTT (90%), 
and 27 of 30 FFPE (90%) specimens. The results included 
11 BRAF mutations and 18 wild types (WTs) for the air-
dried CTT specimens, 13 BRAF mutations and 14 WTs for 
the ethanol-fixed CTT specimens, and 13 BRAF mutations 
and 14 WTs for the FFPE specimens ❚Table 1❚. The con-
cordance rate was 96% between air-dried and ethanol-fixed 
CTT specimens, 88% between air-dried CTT and FFPE 
specimens, and 92% between ethanol-fixed CTT and FFPE 
specimens. There was one case in which mutation was 
detected on CTT specimens but not on the corresponding 
FFPE tissues (case 23). Conversely, two other cases had 
mutations identified on the FFPE tissue but not on the cor-
responding CTT specimen (cases 5 and 6). Using the FFPE 
tissue as the gold standard, the sensitivity and specificity for 
detection of BRAF mutation on CTT direct smears were 85% 
and 93%, respectively.
The original FNA diagnoses of these 30 cases included 
three benign nonneoplastic lesions, six FLUS, one follicular 
neoplasm, six cases suspicious for PTC, and 14 PTCs (Table 
1). All the benign and malignant FNA diagnoses were 
confirmed by the follow-up thyroidectomies. The follow-
up of six cases suspicious for PTC revealed two PTCs, 
three follicular variant PTCs, and one follicular carcinoma. 
The follow-up of the follicular neoplasm case revealed a 
follicular adenoma on the resection specimen. Of the six 
❚Table 1❚
Comparison of BRAF Mutation Results Between Cytologic and Formalin-Fixed, Paraffin-Embedded Tissue
FNA Dx DNA-AD, ng BRAF-AD DNA-EF, ng BRAF-EF SP Dx DNA-FFPE, ng BRAF-FFPE
1 B 8.6 WT 31.5 Failed B 161.5 WT
2 B 5 WT 0.6 WT B 72.4 WT
3 B 5.3 WT 0.2 WT B 107.2 WT
4 FLUS 2.4 WT 4.3 Failed B 147.6 Failed
5 FLUS 1.7 WT 7.9 WT PTC 32 V600E
6 FLUS 1.4 WT 1.3 Failed PTC 176.5 V600E
7 FLUS 6.4 WT 6.7 WT FVPTC 223.9 WT
8 FLUS 6.3 WT 30.7 WT B 207.9 WT
9 FLUS 5.2 WT 20 WT B 44.7 WT
10 FN 13.4 WT 25.1 WT FA 100.8 WT
11 PTC 9.4 WT 1.7 V600E PTC 258.8 V600E
12 PTC 5.1 V600E 1.4 V600E PTC 266.1 V600E
13 PTC 3.5 V600E 5.5 V600E PTC 90.4 V600E
14 PTC 1.1 V600E 18.6 V600E PTC 68.9 V600E
15 PTC 1.5 V600E 24 V600E PTC 153.6 V600E
16 PTC 7.2 V600E 3.7 V600E PTC 217.2 V600E
17 PTC 3.8 V600E 4.1 V600E PTC 100.1 V600E
18 PTC 4.3 V600E 14.8 V600E PTC 155.2 V600E
19 PTC 3.4 V600E 27.1 V600E PTC 265.3 V600E
20 PTC 1.2 V600E 2.9 V600E PTC 109.5 V600E
21 PTC 3.6 V600E 15.8 V600E PTC 410.2 V600E
22 PTC 16.9 WT 7.8 WT PTC 425.1 WT
23 PTC 0.2 Failed 1.2 V600E PTC 75.2 WT
24 PTC 3.7 WT 0.1 WT PTC 86.8 WT
25 S/PTC 2.1 WT 2.2 WT PTC 263.3 Failed
26 S/PTC 1.3 V600E 13.2 V600E FVPTC 123.6 Failed
27 S/PTC 3.8 WT 3 WT PTC 317.8 WT
28 S/PTC 1.6 WT 9 WT FC 96.2 WT
29 S/PTC 3.5 WT 0.2 WT FVPTC 56.3 WT
30 S/PTC 3.2 WT 8.6 WT FVPTC 28.1 WT
AD, air-dried cell transfer cytology; B, benign nonneoplastic lesion; Dx, diagnosis; EF, ethanol-fixed cell transfer cytology; FA, follicular adenoma; FC, follicular carcinoma; 
FFPE, formalin fixed, paraffin embedded; FLUS, follicular lesion of undetermined significance; FN, follicular neoplasm; FNA, fine-needle aspiration; FVPTC, follicular 
variant of papillary thyroid carcinoma; PTC, papillary thyroid carcinoma; SP, surgical pathology; S/PTC, suspicious for papillary thyroid carcinoma; WT, wild type.








AJCP / Original Article
 Am J Clin Pathol 2015;143:500-504 503
 DOI: 10.1309/AJCP5BG0KUEOJCVS 
© American Society for Clinical Pathology
FLUS cases, the follow-up showed three benign nonneo-
plastic lesions, two PTCs, and one follicular variant of PTC. 
BRAF V600E mutation was noted in 15 cases, of which the 
thyroidectomy specimens showed classic PTC in 14 cases 
and follicular variant PTC in one case. Ethanol-fixed CTT 
specimens had the same BRAF mutation detection rate as 
FFPE specimens (13/15), while the air-dried specimens had 
a lower rate (11/15).
Discussion
BRAF mutation is the single most common mutation 
associated with thyroid carcinoma, and it is a potential 
stratification tool for planning the extent of thyroid surgery 
and as a potential therapeutic target in PTC.9 The addi-
tion of molecular analysis of BRAF mutation on cytologic 
specimens has increased 20% to 25% yield of sensitivity 
in the detection of thyroid cancer compared with cytology 
alone.10-12 CTT is a feasible method for obtaining cellular 
material from FNA direct smears for immunocytochemical 
stains.13 It has also proven useful for obtaining adequate 
DNA from tumor cells for the molecular testing to identify 
EGFR and KRAS mutations from FNA smears of adeno-
carcinoma of the lung. Wu et al8 have found a high agree-
ment rate (97%) between the specimens obtained from the 
FNA smears by CTT and FFPE tissue for EGFR and KRAS 
mutations in cases of pulmonary adenocarcinoma. In our 
institution, cell blocks of the thyroid FNA usually contain 
scant cellularity. The ability to visualize and select the 
abnormal cells through CTT provides an advantage over 
the recut of the cell block tissue, especially when the tumor 
cells are fewer and the surrounding normal tissues are 
abundant in the block, factors that may cause a false-nega-
tive result for the cell block tissue. In the current study, we 
confirm the usefulness of CTT to obtain adequate materials 
for BRAF molecular analysis from thyroid FNA smears. 
We required at least 100 cells to be transferred for each 
case, and BRAF testing was successfully performed on 
29 of 30 air-dried (97%) and 27 of 30 ethanol-fixed cell-
transferred smears (90%) that compared with a test failure/
invalid rate of 9.2% for Sanger sequencing.14 There was a 
96% agreement of the final molecular results between the 
two methods. The agreement between cytologic and FFPE 
specimens was 88% for air-dried and 92% for ethanol-
fixed CTT. Both air-dried and ethanol-fixed smears are 
feasible for providing DNA materials for molecular testing 
for BRAF mutations. However, in our small series of study, 
ethanol-fixed CTT showed a slightly higher successful rate 
in detecting BRAF mutation compared with the air-dried 
CTT (13 vs 11 cases), but the number of cases is too small 
to draw a conclusion.
There were three discordant cases in our study. Two 
false-negative cases with cytologic diagnosis of FLUS 
revealed WT on CTT smears, while the corresponding FFPE 
tissues, which were diagnostic of papillary carcinoma, dem-
onstrated BRAF V600E mutations (cases 5 and 6). Retro-
spective review of these two cases showed abundant colloid 
with scattered macrophages and few groups of atypical fol-
licular epithelium on the smears. The false-negative molecu-
lar testing results on these two FLUS cases are most likely 
due to low volume of tumor cells with contaminant benign 
follicular cells and colloid. The third discrepant case in our 
study was a case of papillary carcinoma (case 23) that was 
diagnosed by cytology and confirmed on thyroidectomy. In 
this case, BRAF mutation was found on the ethanol-fixed 
CTT cytologic samples, but the corresponding FFPE tissue 
demonstrated only WT. False-positive BRAF mutation has 
been shown to be rare by Kim et al,11 who used dual-priming 
oligonucleotide–based multiplex PCR analysis to identify 
five cases of false-positive BRAF V600E mutation in a study 
of 1,074 patients. A false-positive result can be due to sam-
pling error; a small focus of micropapillary carcinoma might 
have not been sampled when the thyroidectomy specimen 
was examined. The discrepancy of this last case (case 23) is 
most likely due to BRAF genetic heterogeneity even though 
intratumoral BRAF genetic heterogeneity rarely occurs in 
PTC. Walts et al15 used the PCR method for BRAF V600E 
detection and discovered discordant BRAF results in 4.8% 
of the pairs studied for PTC. The other possibility is that the 
decalcification process of the targeted tumor nodule on case 
23 might have caused degeneration of the DNA materials, 
which may also contribute to the false-negative BRAF muta-
tional result on the FFPE tissue.7
CTT has been proven useful to provide adequate DNA 
materials for the detection of BRAF mutations in cases with 
cytologic diagnoses of papillary carcinoma or suspicious for 
papillary carcinoma. In our study, there was 100% sensitiv-
ity using ethanol-fixed CTT cytologic materials for BRAF 
detection in this group of patients. One possible potential for 
the application of CTT on direct smears of the thyroid aspi-
rates is to triage the cases with indeterminate FNA diagnoses 
such as FLUS or “atypia of undetermined significance.” 
BRAF has a very high cancer predictive rate; in the study by 
Kim et al,11 221 (98%) of 226 cases of BRAF V600E–posi-
tive FNA cytology correlated with thyroid carcinoma on the 
follow-up thyroidectomies, so positive BRAF will warrant a 
total thyroidectomy with possible neck lymph node dissec-
tion, even with indeterminate FNA diagnoses for patients. 
CTT provides a useful option for cytology specimens in 
which cell blocks lack adequate cellularity for ancillary studies.
One of the advantages of CTT over a common micro-
dissection technique (using a scalpel to scrape the cells 
from the slides) is the capability of CTT to perform 
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immunocytochemistry at the same time. Immunocytochem-
istry on CTT smears has been validated and routinely per-
formed in our laboratory.13 Recently immunocytochemistry 
in the detection of BRAF V600E in the FNA of PTC was 
validated on cell block slides.7 Potentially, we can perform 
immunocytochemistry for BRAF mutation on CTT first as 
a cheaper screening test and then conduct molecular testing 
as the confirmation method either on the same CTT pieces 
that immunocytochemistry was performed on or on different 
pieces of CTT that are present on the same smears.
Although all six FLUS cases in our study showed no 
evidence of BRAF mutations on CTT samples, it may poten-
tially provide additional sensitivity for the diagnosis of PTC 
in cases of indeterminate cytologic diagnoses. A large-scale 
correlation study is needed to verify the utility of CTT for 
thyroid FNA cases with indeterminate diagnoses.
Address reprint requests to Dr Wu: Dept of Pathology and 
Laboratory Medicine, Indiana University School of Medicine, 350 
W 11th St, IUHPL-4086, Indianapolis, IN 46202; hhwu@iupui.edu.
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